TrialInternational journal of clinical oncology2024

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.

Nobuhiko Oridate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.